Epigenetics Diagnostic Market Size, Trends and Insights By Product Type (Enzymes, Instruments and Consumables, Kits, Reagents), By Technology (DNA Methylation, Histone Methylation, Others), By Application (Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Bio-Techne. (U.S.)
- Promega Corporation (U.S.)
- GeneTex Inc. (U.S.)
- Pacific Biosciences of California Inc. (U.S.)
- Illumina Inc. (U.S.)
- Merck KGaA (Germany)
- Others
Reports Description
Global Epigenetics Diagnostic Market was valued at USD 15.7 Billion in 2024 and is expected to reach USD 41.6 Billion by 2033, at a CAGR of 14.2% during the forecast period 2024 – 2033.
Epigenetic diagnostics is the study of epigenetic alterations such as DNA methylation, histone modifications, and non-coding RNA expression patterns to determine disease risk, prognosis, and therapy response, opening the way for personalized medicine solutions.
Epigenetics Diagnostic Market: Growth Factors
High demand in drug discovery and development
The expanding use of epigenetics in drug research and development has greatly accelerated the growth of the epigenetic diagnostics industry. Epigenetics, the study of heritable changes in gene expression that do not entail mutations in the DNA sequence, is critical for understanding disease causes and discovering new treatment targets.
As researchers explore further into the complex epigenetic changes linked with many diseases, such as cancer, neurological disorders, and autoimmune ailments, they discover new avenues for developing tailored medicines.
Epigenetic medicines, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, are increasingly being investigated for their ability to change abnormal epigenetic marks and restore normal gene expression patterns in sick cells.
Furthermore, the discovery of epigenetic biomarkers such as DNA methylation patterns and histone alterations presents intriguing opportunities for early illness identification, patient stratification, and therapy response monitoring.
This synergy between advanced epigenetic research and the demand for precision medicine promotes the creation of novel epigenetics diagnostics methods and technologies, hence propelling the epigenetics diagnostics market forward. As the research advances, utilizing epigenetic insights holds enormous promise for changing personalized healthcare and improving patient outcomes.
Growing prevalence of cancer
The increasing prevalence of cancer has prompted considerable advances in diagnostic procedures, particularly in the field of epigenetics. Epigenetics, the study of heritable changes in gene expression that do not need mutations to the underlying DNA sequence, has emerged as a viable approach to cancer detection and monitoring.
Unlike genetic mutations, epigenetic changes are reversible, providing dynamic insights into cancer formation and progression. Epigenetic changes, such as DNA methylation patterns and histone modifications, act as biomarkers for different types of cancer, giving clinicians significant tools for accurate diagnosis and prognosis.
Furthermore, the non-invasive nature of epigenetic assays, which generally use readily available physiological fluids such as blood or urine, allows for continuous monitoring of cancer patients and rapid alterations in treatment methods.
As the demand for accurate and personalized cancer diagnostics grows, fuelled by the rising global cancer burden, the epigenetics diagnostics market is poised for significant growth, driven by innovative technologies and robust research efforts aimed at unlocking the epigenome’s diagnostic potential.
Over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. The rapidly growing global cancer burden reflects both population ageing and growth, as well as changes to people’s exposure to risk factors, several of which are associated with socioeconomic development.
Tobacco, alcohol and obesity are key factors behind the increasing incidence of cancer, with air pollution still a key driver of environmental risk factors.
Epigenetics Diagnostic Market: Restraints
Complexity in data interpretation
The complex nature of data interpretation creates considerable obstacles for the epigenetics diagnostics sector. Epigenetics, the study of changes in gene expression or cellular phenotype induced by causes other than changes in the underlying DNA sequence, is primarily reliant on complex data analysis for diagnosis.
This complexity stems from the wide range of epigenetic alterations and their interactions, necessitating advanced computational tools and analytical methodologies. Epigenetic patterns are regulated by a variety of factors, including environmental exposures, lifestyle choices, and developmental phases, making epigenetic data interpretation inherently complex.
Furthermore, the multidimensional structure of epigenetic data, such as DNA methylation, histone modifications, and non-coding RNA expression, makes it difficult to differentiate important signals from background noise.
Furthermore, the dynamic nature of epigenetic regulation adds to the complexity by allowing these alterations to vary over time or in response to external stimuli.
As a result, effectively analysing epigenetic data to extract therapeutically relevant insights for diagnostic purposes necessitates strong bioinformatics techniques, advanced statistical methodology, and multidisciplinary collaboration among biologists, bioinformaticians, and clinicians.
Epigenetics Diagnostic Market: Opportunities
Innovation in Next-Generation Sequencing
Innovation in Next-Generation Sequencing (NGS) has accelerated epigenetics diagnostics, altering our understanding of gene control and disease causes. NGS technologies allow for the thorough investigation of DNA methylation patterns, modifications to histone proteins, chromatin accessibility, and non-RNA coding expression, providing unprecedented insight into the epigenetic landscape of cells and tissues.
This high-throughput technique enables researchers and physicians to investigate epigenetic changes throughout the genome with unprecedented accuracy and resolution. Furthermore, NGS-based epigenetics diagnostics have advantages such as sensitivity, specificity, and scalability, making them ideal for biomarker identification, patient classification, and tracking treatment response.
As NGS technologies advance in sequencing speed, accuracy, and cost-effectiveness, the epigenetics diagnostics industry is primed for significant expansion, spurring innovation and improving the ability to detect and manage complex diseases at the epigenetic level.
Epigenetics Diagnostic Market: Segmentation Analysis
Global Epigenetics Diagnostic market is segmented by product type, technology, application, and region. Based on product type, the market is classified into enzymes, instruments and consumables, kits and reagents.
Reagents dominated the market in 2023 with a market share of 60.3% and are expected to keep their dominance during the forecast period 2024-2033 Reagents play an important role in the advancement of epigenetics diagnostics, encouraging innovation and extending diagnostic technology capabilities.
Epigenetics is the study of heritable changes in gene expression that do not need mutations to the underlying DNA sequence, and its diagnostic applications are critical for understanding a variety of diseases, including cancer and neurological disorders.
Reagents designed for epigenetic analysis, such as DNA methylation and histone modification assays, allow researchers and physicians to discover subtle epigenetic changes linked with diseases. These reagents frequently comprise antibodies, DNA-modifying enzymes, and specialized chemical compounds that target certain epigenetic markers or proteins.
Furthermore, the creation of high-throughput screening methods and next-generation sequencing platforms is strongly reliant on epigenetic-optimized reagents, which allow for the more sensitive and accurate analysis of large-scale epigenomic data sets.
Based on technology, the market is classified into DNA methylation, histone methylation and Others. DNA Methylation dominated the market in 2023 with a market share of 45.5% and is expected to keep its dominance during the forecast period 2024-2033.
DNA methylation is a critical biomarker for a variety of diseases and ailments, which drives the growth of the epigenetics diagnostics industry. DNA methylation profiles have been related to a variety of diseases, including cancer, neurological disorders, autoimmune diseases, and developmental abnormalities, yielding vital information on disease mechanisms and potential diagnostic markers.
Advances in high-throughput sequencing technologies and bioinformatics tools have allowed for the rapid and cost-effective profiling of DNA methylation patterns across the genome, enabling the discovery of novel biomarkers and the development of diagnostic assays with high sensitivity and specificity.
As researchers continue to understand the complexities of epigenetic regulation and its consequences for human health, the demand for epigenetics diagnostics based on DNA methylation analysis is expected to rise, fuelling development and growth in the diagnostics market for personalized and precision medicine applications.
Based on application, the market is classified into oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases and others. Oncology dominated the market in 2023 with a market share of 34.5% and is expected to keep its dominance during the forecast period 2024-2033.
Oncology plays a pivotal role in driving the epigenetics diagnostics market due to the intricate relationship between epigenetic alterations and cancer development. Epigenetics is the study of DNA and histone protein changes that influence gene expression while leaving the underlying DNA sequence unchanged.
Epigenetic biomarkers have multiple benefits in oncology, including their capacity to detect early-stage malignancies, predict patient outcomes, and guide treatment decisions. Thus, the interaction of oncology and epigenetics continues to drive diagnostic advances, influencing the landscape of precision therapy for cancer patients.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 15.7 Billion |
| Projected Market Size in 2033 | USD 41.6 Billion |
| Market Size in 2023 | USD 14.3 Billion |
| CAGR Growth Rate | 14.2% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Product Type, Technology, Application and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Epigenetics Diagnostic Market: Regional Analysis
By region, Epigenetics Diagnostic market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. North America dominated the global Epigenetics Diagnostic market in 2023 with a market share of 41.1% and is expected to keep its dominance during the forecast period 2024-2033.
North America has an advanced healthcare infrastructure and a dynamic research ecosystem, which promotes innovation and development in epigenetic diagnostic technology. Leading academic and research organizations, as well as biotechnology and pharmaceutical businesses, are all actively investigating epigenetic mechanisms and their implications for illness detection and therapy.
The vast patient population in North America, combined with the rising frequency of chronic diseases that include cancer, diabetes, and cardiovascular disorders, creates a significant demand for accurate and timely diagnostic tools.
Epigenetics diagnostics have the potential to improve disease detection, prognosis, and individualized treatment techniques, which aligns with the region’s focus on precision medicine. Moreover, favourable government initiatives and funding support for genomics and personalized medicine research have accelerated the use of epigenetic diagnostics in North America.
Epigenetics Diagnostic Market: Recent Developments
- In January 2024, BD announced its partnership with Hamilton Company. The company’s collaboration focuses on developing robotics-compatible and automated application reagent kits to standardize and eliminate human error in large-scale single-cell Epigenetics Diagnostics.
- In January 2024, Thermo Fisher Scientific Inc. collaborated with Akoya Biosciences, Inc. The agreement simplifies the procedure of whole-slide, multiomic imaging. This combination technique provides a more thorough understanding of cell phenotypes and circumstances by studying protein and RNA, which is critical in field of cancer research.
- In November 2023, Illumina launched an improved liquid biopsy technique meant to enable thorough genetic profiling of solid cancers.
List of the prominent players in the Epigenetics Diagnostic Market:
- Bio-Techne. (U.S.)
- Promega Corporation (U.S.)
- GeneTex Inc. (U.S.)
- Pacific Biosciences of California Inc. (U.S.)
- Illumina Inc. (U.S.)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- Hoffmann-La Roche Ltd (Switzerland)
- Eisai Co Ltd. (Japan)
- Novartis AG (Switzerland)
- Abcam plc (U.K.)
- Diagenode s.a. (U.S.)
- Active Motif Inc. (U.S.)
- Zymo Research Corporation. (U.S.)
- Thermo Fisher Scientific (U.S.)
- Cellcentric (Germany)
- Syndax (U.S.)
- New England Biolabs (U.S.)
- Epizyme, Inc. (U.S.)
- Domainex (U.K.)
- Agilent Technologies Inc. (U.S.)
- Others
These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.
The Epigenetics Diagnostic Market is segmented as follows:
By Product Type
- Enzymes
- Instruments and Consumables
- Kits
- Reagents
By Technology
- DNA Methylation
- Histone Methylation
- Others
By Application
- Oncology
- Metabolic Diseases
- Developmental Biology
- Immunology
- Cardiovascular Diseases
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Epigenetics Diagnostic Market, (2024 – 2033) (USD Billion)
- 2.2 Global Epigenetics Diagnostic Market: snapshot
- Chapter 3. Global Epigenetics Diagnostic Market – Industry Analysis
- 3.1 Epigenetics Diagnostic Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 High demand in drug discovery and development
- 3.2.2 Growing prevalence of cancer
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product Type
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By Application
- Chapter 4. Global Epigenetics Diagnostic Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Epigenetics Diagnostic Market: company market share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Epigenetics Diagnostic Market – Product Type Analysis
- 5.1 Global Epigenetics Diagnostic Market Overview: By Product Type
- 5.1.1 Global Epigenetics Diagnostic Market Share, By Product Type, 2023 and 2033
- 5.2 Enzymes
- 5.2.1 Global Epigenetics Diagnostic Market by Enzymes, 2024 – 2033 (USD Billion)
- 5.3 Instruments and Consumables
- 5.3.1 Global Epigenetics Diagnostic Market by Instruments and Consumables, 2024 – 2033 (USD Billion)
- 5.4 Kits
- 5.4.1 Global Epigenetics Diagnostic Market by Kits, 2024 – 2033 (USD Billion)
- 5.5 Reagents
- 5.5.1 Global Epigenetics Diagnostic Market by Reagents, 2024 – 2033 (USD Billion)
- 5.1 Global Epigenetics Diagnostic Market Overview: By Product Type
- Chapter 6. Global Epigenetics Diagnostic Market – Technology Analysis
- 6.1 Global Epigenetics Diagnostic Market Overview: By Technology
- 6.1.1 Global Epigenetics Diagnostic Market Share, By Technology, 2023 and 2033
- 6.2 DNA Methylation
- 6.2.1 Global Epigenetics Diagnostic Market by DNA Methylation, 2024 – 2033 (USD Billion)
- 6.3 Histone Methylation
- 6.3.1 Global Epigenetics Diagnostic Market by Histone Methylation, 2024 – 2033 (USD Billion)
- 6.4 Others
- 6.4.1 Global Epigenetics Diagnostic Market by Others, 2024 – 2033 (USD Billion)
- 6.1 Global Epigenetics Diagnostic Market Overview: By Technology
- Chapter 7. Global Epigenetics Diagnostic Market – Application Analysis
- 7.1 Global Epigenetics Diagnostic Market Overview: By Application
- 7.1.1 Global Epigenetics Diagnostic Market Share, By Application, 2023 and 2033
- 7.2 Oncology
- 7.2.1 Global Epigenetics Diagnostic Market by Oncology, 2024 – 2033 (USD Billion)
- 7.3 Metabolic Diseases
- 7.3.1 Global Epigenetics Diagnostic Market by Metabolic Diseases, 2024 – 2033 (USD Billion)
- 7.4 Developmental Biology
- 7.4.1 Global Epigenetics Diagnostic Market by Developmental Biology, 2024 – 2033 (USD Billion)
- 7.5 Immunology
- 7.5.1 Global Epigenetics Diagnostic Market by Immunology, 2024 – 2033 (USD Billion)
- 7.6 Cardiovascular Diseases
- 7.6.1 Global Epigenetics Diagnostic Market by Cardiovascular Diseases, 2024 – 2033 (USD Billion)
- 7.7 Others
- 7.7.1 Global Epigenetics Diagnostic Market by Others, 2024 – 2033 (USD Billion)
- 7.1 Global Epigenetics Diagnostic Market Overview: By Application
- Chapter 8. Epigenetics Diagnostic Market – Regional Analysis
- 8.1 Global Epigenetics Diagnostic Market Regional Overview
- 8.2 Global Epigenetics Diagnostic Market Share, by Region, 2023 & 2033 (USD Billion)
- 8.3. North America
- 8.3.1 North America Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.3.1.1 North America Epigenetics Diagnostic Market, by Country, 2024 – 2033 (USD Billion)
- 8.3.1 North America Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.4 North America Epigenetics Diagnostic Market, by Product Type, 2024 – 2033
- 8.4.1 North America Epigenetics Diagnostic Market, by Product Type, 2024 – 2033 (USD Billion)
- 8.5 North America Epigenetics Diagnostic Market, by Technology, 2024 – 2033
- 8.5.1 North America Epigenetics Diagnostic Market, by Technology, 2024 – 2033 (USD Billion)
- 8.6 North America Epigenetics Diagnostic Market, by Application, 2024 – 2033
- 8.6.1 North America Epigenetics Diagnostic Market, by Application, 2024 – 2033 (USD Billion)
- 8.7. Europe
- 8.7.1 Europe Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.7.1.1 Europe Epigenetics Diagnostic Market, by Country, 2024 – 2033 (USD Billion)
- 8.7.1 Europe Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.8 Europe Epigenetics Diagnostic Market, by Product Type, 2024 – 2033
- 8.8.1 Europe Epigenetics Diagnostic Market, by Product Type, 2024 – 2033 (USD Billion)
- 8.9 Europe Epigenetics Diagnostic Market, by Technology, 2024 – 2033
- 8.9.1 Europe Epigenetics Diagnostic Market, by Technology, 2024 – 2033 (USD Billion)
- 8.10 Europe Epigenetics Diagnostic Market, by Application, 2024 – 2033
- 8.10.1 Europe Epigenetics Diagnostic Market, by Application, 2024 – 2033 (USD Billion)
- 8.11. Asia Pacific
- 8.11.1 Asia Pacific Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.11.1.1 Asia Pacific Epigenetics Diagnostic Market, by Country, 2024 – 2033 (USD Billion)
- 8.11.1 Asia Pacific Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.12 Asia Pacific Epigenetics Diagnostic Market, by Product Type, 2024 – 2033
- 8.12.1 Asia Pacific Epigenetics Diagnostic Market, by Product Type, 2024 – 2033 (USD Billion)
- 8.13 Asia Pacific Epigenetics Diagnostic Market, by Technology, 2024 – 2033
- 8.13.1 Asia Pacific Epigenetics Diagnostic Market, by Technology, 2024 – 2033 (USD Billion)
- 8.14 Asia Pacific Epigenetics Diagnostic Market, by Application, 2024 – 2033
- 8.14.1 Asia Pacific Epigenetics Diagnostic Market, by Application, 2024 – 2033 (USD Billion)
- 8.15. Latin America
- 8.15.1 Latin America Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.15.1.1 Latin America Epigenetics Diagnostic Market, by Country, 2024 – 2033 (USD Billion)
- 8.15.1 Latin America Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.16 Latin America Epigenetics Diagnostic Market, by Product Type, 2024 – 2033
- 8.16.1 Latin America Epigenetics Diagnostic Market, by Product Type, 2024 – 2033 (USD Billion)
- 8.17 Latin America Epigenetics Diagnostic Market, by Technology, 2024 – 2033
- 8.17.1 Latin America Epigenetics Diagnostic Market, by Technology, 2024 – 2033 (USD Billion)
- 8.18 Latin America Epigenetics Diagnostic Market, by Application, 2024 – 2033
- 8.18.1 Latin America Epigenetics Diagnostic Market, by Application, 2024 – 2033 (USD Billion)
- 8.19. The Middle-East and Africa
- 8.19.1 The Middle-East and Africa Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.19.1.1 The Middle-East and Africa Epigenetics Diagnostic Market, by Country, 2024 – 2033 (USD Billion)
- 8.19.1 The Middle-East and Africa Epigenetics Diagnostic Market, 2024 – 2033 (USD Billion)
- 8.20 The Middle-East and Africa Epigenetics Diagnostic Market, by Product Type, 2024 – 2033
- 8.20.1 The Middle-East and Africa Epigenetics Diagnostic Market, by Product Type, 2024 – 2033 (USD Billion)
- 8.21 The Middle-East and Africa Epigenetics Diagnostic Market, by Technology, 2024 – 2033
- 8.21.1 The Middle-East and Africa Epigenetics Diagnostic Market, by Technology, 2024 – 2033 (USD Billion)
- 8.22 The Middle-East and Africa Epigenetics Diagnostic Market, by Application, 2024 – 2033
- 8.22.1 The Middle-East and Africa Epigenetics Diagnostic Market, by Application, 2024 – 2033 (USD Billion)
- Chapter 9. Company Profiles
- 9.1 Bio-Techne. (U.S.)
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Promega Corporation (U.S.)
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 GeneTex Inc. (U.S.)
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Pacific Biosciences of California Inc. (U.S.)
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Illumina Inc. (U.S.)
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Merck KGaA (Germany)
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 QIAGEN (Germany)
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 F. Hoffmann-La Roche Ltd (Switzerland)
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Eisai Co Ltd. (Japan)
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Novartis AG (Switzerland)
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Abcam plc (U.K.)
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 Diagenode s.a. (U.S.)
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Active Motif Inc. (U.S.)
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 Zymo Research Corporation. (U.S.)
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.15 Thermo Fisher Scientific (U.S.)
- 9.15.1 Overview
- 9.15.2 Financials
- 9.15.3 Product Portfolio
- 9.15.4 Business Strategy
- 9.15.5 Recent Developments
- 9.16 Cellcentric (Germany)
- 9.16.1 Overview
- 9.16.2 Financials
- 9.16.3 Product Portfolio
- 9.16.4 Business Strategy
- 9.16.5 Recent Developments
- 9.17 Syndax (U.S.)
- 9.17.1 Overview
- 9.17.2 Financials
- 9.17.3 Product Portfolio
- 9.17.4 Business Strategy
- 9.17.5 Recent Developments
- 9.18 New England Biolabs (U.S.)
- 9.18.1 Overview
- 9.18.2 Financials
- 9.18.3 Product Portfolio
- 9.18.4 Business Strategy
- 9.18.5 Recent Developments
- 9.19 Epizyme
- 9.19.1 Overview
- 9.19.2 Financials
- 9.19.3 Product Portfolio
- 9.19.4 Business Strategy
- 9.19.5 Recent Developments
- 9.20 Agilent Technologies Inc. (U.S.)
- 9.20.1 Overview
- 9.20.2 Financials
- 9.20.3 Product Portfolio
- 9.20.4 Business Strategy
- 9.20.5 Recent Developments
- 9.21 Domainex (U.K.)
- 9.21.1 Overview
- 9.21.2 Financials
- 9.21.3 Product Portfolio
- 9.21.4 Business Strategy
- 9.21.5 Recent Developments
- 9.22 Others
- 9.22.1 Overview
- 9.22.2 Financials
- 9.22.3 Product Portfolio
- 9.22.4 Business Strategy
- 9.22.5 Recent Developments
- 9.1 Bio-Techne. (U.S.)
List Of Figures
Figures No 1 to 29
List Of Tables
Tables No 1 to 77
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Bio-Techne. (U.S.)
- Promega Corporation (U.S.)
- GeneTex Inc. (U.S.)
- Pacific Biosciences of California Inc. (U.S.)
- Illumina Inc. (U.S.)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- Hoffmann-La Roche Ltd (Switzerland)
- Eisai Co Ltd. (Japan)
- Novartis AG (Switzerland)
- Abcam plc (U.K.)
- Diagenode s.a. (U.S.)
- Active Motif Inc. (U.S.)
- Zymo Research Corporation. (U.S.)
- Thermo Fisher Scientific (U.S.)
- Cellcentric (Germany)
- Syndax (U.S.)
- New England Biolabs (U.S.)
- Epizyme, Inc. (U.S.)
- Domainex (U.K.)
- Agilent Technologies Inc. (U.S.)
- Others
FAQs
The major driver for the Epigenetics Diagnostic market is high demand in drug discovery and development and growing prevalence of cancer.
The “Oncology” had the largest share in the global market for Epigenetics Diagnostic.
The “Enzymes” category dominated the market in 2023.
The key players in the market are Bio-Techne. (U.S.), Promega Corporation (U.S.), GeneTex Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Illumina Inc. (U.S.), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co Ltd. (Japan), Novartis AG (Switzerland), Abcam plc (U.K.), Diagenode s.a. (U.S.), Active Motif Inc. (U.S.), Zymo Research Corporation. (U.S.), Thermo Fisher Scientific (U.S.), Cellcentric (Germany), Syndax (U.S.), New England Biolabs (U.S.), Epizyme, Inc. (U.S.), Domainex (U.K.), Agilent Technologies Inc. (U.S.), Others.
“North America” had the largest share in the Epigenetics Diagnostic Market.
The global market is projected to grow at a CAGR of 14.2% during the forecast period, 2024-2033.
The Epigenetics Diagnostic Market size was valued at USD 15.7 Billion in 2024.